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ABSTRACT  
Daehlin, Kelsey. Effects of Exercise on Myogenic Regulatory Factors in Cancer 
Cachexia-Induced Skeletal Muscle Wasting. Unpublished Master of Science 
thesis, University of Northern Colorado, 2020. 
 
Cancer cachexia is a complex multiorgan syndrome that affects bodily systems 
such as liver, brain, fat tissue, and skeletal muscle. It is a major factor that decreases 
quality of life in cancer patients and is related to about 20% of cancer deaths, however 
exercise has shown to be effective in helping combat the muscle wasting effects that 
cancer cachexia has on the body. Cachexia characterized by skeletal muscle wasting 
which may be caused by downregulation of positive myogenic regulatory factors such as 
MyoD and myogenin, and upregulation of negative myogenic regulatory factors such as 
myostatin and MuRF-1. While it is known that exercise is effective in combatting skeletal 
muscle wasting, little is known about how different modes of exercise affect cachexia. 
The purpose of this study was to determine the effects of an endurance training protocol, 
a resistance training protocol, and a combined endurance and resistance training protocol 
in cancer cachexia on specific positive myogenic regulatory factors such as MyoD and 
myogenin, and on negative myogenic regulatory factors myostatin and MuRF-1.  
 Six week old male Balb/c mice were randomly assigned to one of the following 
groups: sedentary+control (SED+Control), sedentary+tumor  (SED+Tumor), treadmill 
training+tumor (TM+Tumor), resistance training+tumor (RT+Tumor), and combined 
treadmill training and resistance training+ tumor (COMBO+Tumor). TM mice were 
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trained on a motorized treadmill 5 days per week, RT mice had their food and water 
raised to an end height of 18 cm as a resistance training model, and the COMBO group 
used both protocols. The exercise protocols started at 6 weeks of age.  At 11 weeks old, 
mice in the tumor groups were inoculated with C26 cells that caused cancer cachexia and 
were allowed to remain sedentary (SED, normal cage activity) if in SED+Tumor group; 
the rest of the groups continued with the exercise protocol according to their assigned 
group.  Mice were then sacrificed at 14 weeks of age, and the gastrocnemius was excised. 
Western blotting was then performed to quantify the expression of MyoD, myogenin, 
myostatin, and MuRF-1. A one-way ANOVA found a significant difference between 
groups for myostatin expression (F=4.383, P<0.05), and Tukey’s post hoc testing 
revealed that SED+Tumor had a significantly higher myostatin expression than 
TM+Tumor, RT+Tumor, and COMBO+Tumor. No significant group differences were 
observed for MyoD (F=2.389, p>0.05), myogenin (F=.799, p>0.05), or MuRF-1 
expression (F=1.03, p>0.05). The main finding of this study was that exercised tumor 
bearing animals had significantly less myostatin than sedentary tumor bearing mice 
suggesting that any mode of exercise could have a protective effect on skeletal muscle. 
Because the decrease was evident regardless of exercise mode, including endurance 
training, resistance training, or combined endurance and resistance training may help 
combat the negative effects of cachexia through the suppression of the negative myogenic 
regulatory factor myostatin. 
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CHAPTER I 
INTRODUCTION 
Cancer cachexia is a complex multiorgan syndrome that affects bodily systems 
such as liver, brain, fat, and skeletal muscle. It is a disease that is mainly characterized by 
skeletal muscle wasting that ultimately decreases that ability for cancer patients to 
perform normal activities of daily living (Argiles, Busquets, Lopez-Soriano, Costelli, & 
Penna, 2012; Porporato, 2016). The decreased muscle mass also causes a lower tolerance 
to treatments such as chemotherapy and radiation and a higher mortality rate in cancer 
patients (Smith & Lin, 2013).  Muscle wasting occurs when there is a higher rate of 
catabolism and a lower rate of anabolism (Porporato, 2016; Tisdale, 2009). By examining 
the specific mechanisms in which skeletal muscle mass decreases in cancer cachexia, 
ways can be found to decrease the rate of muscle loss and increase the quality of life in 
cancer patients.  
The Colon-26 (C26) tumor is a type of colon cancer that is known to induce 
cancer cachexia and skeletal muscle wasting. It has been shown that the C26 tumor is 
known to decrease skeletal muscle cross sectional area in both oxidative and glycolytic 
muscle fibers (Aulino et al., 2010). The C26 tumor also increases protein degradation in 
skeletal muscle. However, exercise is known to help combat cancer cachexia. It has been 
shown that exercise has a protective effect on skeletal muscle with cancer cachexia, the 
research in this area is limited and has not focused on one mode of exercise.  
   
 
2  
 
 
 Exercise has been shown to be effective in combatting the muscle wasting effects 
of cachexia, but little is known about how different modes of exercise affect this disease 
(Hardee, Counts, & Carson, 2017). Because skeletal muscle is mostly made up of 
proteins, there is a delicate balance between protein synthesis and protein degradation 
(Bowen, Schuler, & Adams, 2015).  Exercise in general is known to upregulate the 
anabolic pathways and downregulate the catabolic pathways in skeletal muscle, which 
may lead to muscle hypertrophy while decreasing muscle atrophy. In a study that 
included both an endurance and a resistance training protocol with cancer cachexia, it 
was found that anabolic stimulus was increased in the cancer groups that included any 
mode of exercise (Khamoui et al., 2016). Exercise is known to help increase muscle mass 
and have a protective effect on the mitochondria of skeletal muscle which leads to less 
apoptosis of muscle cells (Bowen et al., 2015). 
Skeletal muscle wasting in cancer cachexia is caused by several mechanisms that 
are still being studied. Muscle wasting may be due to downregulation of positive 
myogenic regulatory factors myogenic differentiation protein 1 (MyoD) and myogenin, 
and upregulation of negative myogenic regulatory factors such as myostatin and MuRF-1.  
It has been noted that exercise has a protective effect on skeletal muscle which can help 
to upregulate myogenic regulatory factors positive myogenic regulatory factors and 
decrease the expression of negative myogenic regulatory factors. 
MyoD and myogenin being positive regulators of skeletal muscle can be 
upregulated with exercise. Satellite cells are known to proliferate when there is skeletal 
muscle damage and aid in skeletal muscle hypertrophy (Megeney, Kablar, Garret, 
Andersen, & Rudnicki, 1996). These two positive myogenic regulatory factors are both 
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known to be expressed during satellite cell proliferation and differentiation. MyoD is 
associated with satellite cell activation and the regeneration of skeletal muscle (Lenk, 
Schuler, & Adams, 2010) and is known to be sensitive to mechanical stimulus, such as 
exercise regardless of mode (Legerlotz & Smith, 2008). A large amount of MyoD is 
released when satellite cells proliferate. Myogenin is known to become upregulated 
especially in resistance exercise that causes muscle damage therefore leading to skeletal 
muscle hypertrophy. Myogenin is more specifically known to be expressed when satellite 
cells are in the first stage of proliferation and then decline once the muscles are no longer 
in the stage where muscle hypertrophy is not taking place (Ishido, Kami, & Masuhara, 
2004).  
Because myostatin and muscle ring finger 1 (MuRF-1) are negative regulators of 
skeletal muscle, they are both known to become downregulated with exercise. Increased 
myostatin levels are associated with increased muscle degradation. Myostatin is one of 
the more studied myogenic regulatory factors in cancer cachexia and tends to be 
upregulated in cachectic groups as compared to control groups (Liu et al., 2008). With 
exercise, myostatin becomes downregulated which allows for skeletal muscle 
hypertrophy. MuRF-1 is one of the main ligases whose upregulation is associated with 
increased degradation of skeletal muscle mass (Bowen et al., 2015). Exercise, regardless 
of mode, is known to downregulate MuRF-1 leading to less degradation of skeletal 
muscle (Bowen et al., 2015). This has been shown both with voluntary and involuntary 
exercise. By knowing how these myogenic regulatory factors change with exercise and 
cancer cachexia, it can be determined which pathways should be targeted to help prevent 
skeletal muscle wasting. 
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Statement of Purpose 
The purpose of this study was to determine the effects of an endurance training 
protocol, a resistance training protocol, or a combined endurance and resistance training 
protocol in cancer cachexia on the positive myogenic regulatory factors MyoD and 
myogenin and the negative myogenic regulatory factors myostatin and MuRF-1. This 
study examined both positive and negative myogenic regulatory factors to increase the 
overall understanding of the mechanisms of cancer cachexia.  
Research Hypotheses 
 
H1  The C26 tumor will cause myostatin and MuRF-1 to be upregulated in the 
sedentary tumor group when compared to the sedentary control group. 
 
H2  The C26 tumor will cause myogenin and MyoD to be downregulated in 
the sedentary tumor group when compared the sedentary control group.  
 
H3 MuRF-1 and Myostatin will be downregulated in the C26 tumor groups 
that are resistance trained, endurance trained, and in the combo group. 
 
H4 MyoD and myogenin will become upregulated in the C26 tumor groups 
that are resistance trained, endurance trained, and in the combo group. 
 
H5 The combo group will cause the largest change in myogenic regulatory 
factors, upregulating MyoD and myogenin more than the other groups and 
downregulating myostatin and MuRF-1 more than the other groups.  
 
Significance of Study 
 Cancer cachexia affects many cancer patients and is related to many cancer 
deaths. Models examining exercise as a mechanism to prevent muscle wasting in cancer 
cachexia are not well studied. By determining which myogenic regulatory factors are 
affected by cancer cachexia and exercise, it can be determined how to best prevent the 
loss of skeletal muscle mass and increase the ability of cancer patients to keep up with 
their everyday activities of daily living. Increasing a patient’s muscle mass can also help 
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increase the types of treatments that cancer patients can tolerate. When patients lose a 
large amount of muscle mass through cancer cachexia, the cross sectional area of skeletal 
muscle is known to be decreased. This ultimately reduces the amount of force production 
a patient can produce leading to a decrease in activities of daily living. Some of these 
specific myogenic regulatory factors that are affected by cancer cachexia include MyoD, 
myogenin, myostatin, and MuRF-1. Knowing if these factors are upregulated or 
downregulated with exercise and cachexia will allow for more specific treatments which 
can help maintain a better balance of the myogenic regulatory factors and improve the 
overall quality of life in cancer patients.   
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CHAPTER II 
 
LITERATURE REVIEW 
 
Cancer Cachexia 
 
Cancer cachexia is a major factor that decreases quality of life in a large number 
of cancer patients (Porporato, 2016). Patients are typically considered pre-cachectic if 
they lose less than or equal to five percent of their body mass, and they are categorized as 
cachectic if they have lost between five and twenty percent of their body mass. When a 
patient loses more than twenty percent of their body mass, they are then considered to be 
in the refractory stage of cachexia (Fearon et al., 2011).  
Cachexia is known as a muscle wasting syndrome that is caused by the increase in 
muscle degradation and decrease in muscle anabolism (Porporato, 2016). Skeletal muscle 
consists of a high amount of proteins with a delicate balance between protein synthesis 
and degradation (Bowen et al., 2015). Because cachexia is typically characterized by a 
significant amount of muscle wasting, looking at the specific mechanisms through which 
skeletal muscle wasting occurs, ways of preventing skeletal muscle loss will become 
prevalent. The increase in the ubiquitin-proteasome pathway and decrease in mixed 
muscle synthesis are two of the main pathways that lead to an increase in muscle wasting 
(Brown et al., 2018). Significant losses in body mass can majorly reduce the types of 
treatments that the patient can receive as well as reduces the response to anti-tumor 
treatments (Fearon et al., 2011; Klimek et al., 2010) thus highlighting the importance of 
managing cachexia. This particular condition also decreases patient quality of life 
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through causing decreased functionality and ambulation, as well as increases the rate of 
mortality (Brown et al., 2018). Some of the proposed mechanisms of skeletal muscle 
wasting are an increase in mitochondrial degradation, decreased levels of the positive 
myogenic regulatory factors MyoD and myogenin, and an increase in levels of the 
negative myogenic regulators myostatin and MuRF-1. 
Cachexia and Exercise 
Exercise is known to help increase muscle mass in both healthy and diseased 
individuals (Hardee et al., 2017). Different types of endurance training have been shown 
to help increase food intake and decrease tumor size; however, it cannot be said directly 
whether it was the smaller tumors and increased exercise that helped increase the muscle 
mass (Lenk et al., 2010). Resistance exercise, even though minimally studied with cancer 
cachexia is known to cause an anabolic stimulus which leads to increased signaling that 
causes muscle hypertrophy. In a study that used both resistance and endurance exercise, it 
was found that absolute strength (grip strength normalized to body weight) was 
significantly decreased in mice with the C26 tumor (measured at -7% in the control and -
21% in the mice with the C26 tumor) (Khamoui et al., 2016). The C26 mice also had 
significantly lower gastrocnemius and plantaris mass when compared to the controls; 
however, the post-training values for both resistance and aerobic training tended to be 
increased compared to the pre-test values (+10%) (Khamoui et al., 2016). With aerobic 
training, it has been shown that phosphorylated mTOR to total mTOR ratio was increased 
by 32% in mice with the C26 tumor compared to those with the C26 tumor that were 
sedentary indicating that exercise helps regulate this pathway (Khamoui et al., 2016). 
With exercise, it was found that both the resistance trained and endurance trained mice 
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had reduced body mass when compared to the control group (Khamoui et al., 2016). 
Body mass may have been decreased in the exercised mice due to a volume of exercise 
that was set too high for mice with the C26 tumor.  
Mitochondria 
 
Skeletal muscle mitochondria are known to go through phospholipid bilayer 
remodeling with cancer cachexia which causes them to become dysfunctional (de Castro 
et al., 2019). In a study done on mice, there was a disruption in the morphology of the 
mitochondria as well as an increase in mitophagy in skeletal muscle, but no changes were 
seen in the number of copies of mitochondrial DNA. This means that selective 
degradation of mitochondria was not seen in the cachectic group compared to the weight-
stable group (de Castro et al., 2019). When looking at the mitochondria in a group of rats 
with cancer cachexia, it was seen that there was a 25% and 45% decrease in the 
functionality of mitochondria at three and four weeks after injection of the tumor, 
respectively (Brown et al., 2017). Mitochondrial reactive oxygen species were also found 
to double one week after tumor injection and continued to stay elevated through the third 
week (Brown et al., 2017). This means that there would be more apoptosis of muscle 
cells with an increased level of reactive oxygen species.  
The mitochondrial proteins that code for mitochondrial fission were found to be 
elevated meaning that Drp1 was lowered by 45% by week 4 and Fis 1 was increased by 
80% in the fourth week of the cachectic group. This was being measured in comparison 
to the control group that received PBS as a placebo. (Brown et al., 2017). In this study, it 
was also noted that in week 1, there was an increase in reactive oxygen species in the 
mitochondria, and it was not until week 4 that there was a decrease in muscle mass 
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(Brown et al., 2017). This suggests that the onset of cachexia does not start until week 4, 
and that targeting the mitochondria could be helpful in preventing muscle loss. In 
cachectic patients compared to weight stable cancer patients, mitochondrial area was 
found to be increased (p=0.01) due to swelling of the mitochondria and not due to an 
increase in the number of mitochondria.   
Using a skeletal muscle photomicrograph, it was shown that triads became 
remodeled in the patients considered to be cancer cachectic (greater than 5% body weight 
loss) (de Castro et al., 2019). Furthermore, in a study conducted using mice that were 
injected with a strain of Lewis lung carcinoma that induced cachexia, it was found that on 
average the cachectic rats lost 11.3% of their body weight (Brown et al., 2017). In rats 
that went through the four week progression with the tumor, it was found that the weights 
of the gastrocnemius, plantaris, quadriceps, and soleus were 15 to 20% lower than those 
in the control group (Brown et al., 2017). Overall with cancer cachexia, there is a 
decrease in mitochondria and mitochondrial function and an increase in reactive oxygen 
species leading to apoptosis of muscle cells. 
Myogenic Differentiation Protein 1 
MyoD which is more formally known as myogenic differentiation protein 1 is 
known to regulate muscle differentiation and belongs to the family of myogenic 
regulatory factors (Ishido et al., 2004). MyoD is known to be important in muscle 
differentiation in the process of embryogenic myogenesis; it is known to be under 
different regulatory control during development than during muscle regeneration 
(Kitzmann & Fernandez, 2001). MyoD can be a marker of satellite cell activation due to 
its early release during the proliferation and differentiation during the cell cycle 
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(Legerlotz & Smith, 2008; Megeney et al., 1996). In a study done using a knockout 
model, MyoD-null mice showed less muscle regeneration than those expressing MyoD 
(Megeney et al., 1996). In a study using a tumor bearing model of cachexia in mice, 
muscle weights and MyoD expression with tumor bearing models were decreased by up 
to 45.3% compared to the control group (Liu et al., 2008). While the mechanism is not 
well understood, it is believed that when there is an increase in myostatin, MyoD 
becomes inhibited (Liu et al., 2008). It is not yet known, however, whether it is the 
response in the satellite cells or the response in the myonuclei that is responsible for the 
upregulation of MyoD (Legerlotz & Smith, 2008).  
Both myonuclei and satellite cells are known to express MyoD. Satellite cells 
release a large amount of MyoD when they are activated, and MyoD is highly sensitive to 
both increased and decreased mechanical stress (Legerlotz & Smith, 2008). When 
satellite cells start to proliferate, there is a large increase in the amount of MyoD present 
which means that if there is a stimulus to cause muscle growth, there should also be an 
increase in MyoD expression (Lenk et al., 2010).   
MyoD has also been shown to be linked to the acetylcholine receptors (AChR) in 
the myotubes (Dutton, Simon, & Burden, 1993). These are known to be downregulated in 
muscles that are cachectic (Brown et al., 2018). In a different study using muscle 
denervation, it was found that when there was denervation of the muscle with an 
electrical stimulus, MyoD is upregulated. This may seem contradictory to the other data 
reported, but it is believed that MyoD is increased due to the body trying to preserve 
skeletal muscles and keep them from atrophying (Legerlotz & Smith, 2008). 
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Myogenic Differentiation Protein 1 and Exercise 
In a study that used exercise-trained mice in a tumor bearing model, it was found 
that there was no significant difference in MyoD expression between the mice that were 
exercise trained and the mice that remained sedentary (Khamoui et al., 2016). Because 
satellite cells contain high levels of MyoD, it should be expected that with exercise, there 
will be an increase in the amount of MyoD that is expressed. With resistance exercise, 
MyoD has been shown to increase five times within a twelve hour period in the 
gastrocnemius (Legerlotz & Smith, 2008). It was also found that twenty-four hours after 
six consecutive training days, MyoD levels returned to normal (Legerlotz & Smith, 
2008). There are conflicting data showing either upregulated or downregulated MyoD 
with exercise; however in these studies that show the conflicting data, there is not one 
specific mode of exercise used which likely contributes to these discrepancies (Legerlotz 
& Smith, 2008). Since MyoD is specific to satellite cells and muscle regeneration, the 
mode of exercise most commonly showing increases in MyoD would be high load and 
include eccentric contractions (Legerlotz & Smith, 2008). MyoD expression is likely to 
become more detectable with any type of exercise intervention because MyoD is 
sensitive to any type of mechanical stimulation. (Legerlotz & Smith, 2008).  
Myogenin 
Myogenin is a myogenic regulatory factor that is involved in the process of 
skeletal muscle differentiation and repair. It has been shown that when mice are deficient 
in myogenin, skeletal muscles do not develop correctly (Hasty et al., 1993). When mice 
develop with a myogenin deletion, they tend to be smaller in size as well as having 
altered gene expression (Meadows, Cho, Flynn, & Klein, 2008). Myogenin tends to be 
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expressed more in the slow oxidative muscles (Hughes et al., 1993) and is known to be 
one of the last proteins that is expressed during muscle differentiation and proliferation 
(Megeney et al., 1996). However, in a study that looked at satellite cell proliferation and 
skeletal muscle hypertrophy, it was found that myogenin is expressed at the beginning of 
satellite cell proliferation (Ishido et al., 2004).  In another study that examined 
mitochondrial activity and myogenin, it was seen that when the mitochondria become 
damaged, there is then a decreased expression of myogenin (Rochard et al., 2000). This 
means that in patients or mice with cancer cachexia, there may be a decrease in myogenin 
expression due to mitochondrial damage. With damaged mitochondria there tends to be a 
decrease in circulating hypertrophic factors. While it is well known that myogenin is 
involved in myogenic differentiation, it is still not well known exactly what role 
myogenin plays in adult cells. It has also been shown that myogenin is increased with a 
stimulus and then drops after the muscles no longer have stimulus to hypertrophy 
meaning that once the stimulus goes away, the levels of myogenin will decrease (Ishido 
et al., 2004).   
Myogenin and Exercise 
In a study that was previously mentioned, it was found that there was not a 
significant difference in the exercised C26 mice compared to the exercised control mice 
in myogenin mRNA and protein levels (Khamoui et al., 2016). However, there was a 
difference in the resistance trained mice where there was a 126% increase in myogenin 
mRNA when compared to 150% increase in controls. Myogenin was increased in a study 
that used bouts of resistance exercise; with a second bout of resistance exercise, 
myogenin continued aid in increasing muscle mass. In another study that deleted 
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myogenin in mice, it was found that mice with no myogenin accumulated lactate faster 
with endurance exercise and reached exhaustion quicker than those with myogenin. 
However, over time, metabolism shifted and the performance abilities of the mice 
increased so that the myogenin knockout mice could run faster and longer without 
accumulating as much lactate. This could possibly mean that myogenin negatively 
regulates performance ability by leading to possible changes in skeletal muscle 
metabolism (Flynn, Meadows, Fiorotto, & Klein, 2010). In a study that used mice and 
exercise, it was found that myogenin tended to accumulate with exercise mostly in the 
fast glycolytic fibers (Hughes et al., 1993). It has also been found that with endurance 
exercise, myogenin expression is typically increased (Siu, Donley, Bryner, & Alway, 
2004). While the main function of myogenin in adult muscle is that it is part of the 
satellite cell cycle, it is believed that myogenin may be involved in more than just this 
pathway but more research is needed to determine how else myogenin functions (Siu et 
al., 2004). 
Myostatin 
Myostatin is also a negative regulator of muscle growth and is a member of the 
transforming growth factor-β family and is known to be significantly increased in 
cachectic tumor models (Liu et al., 2008).  Inhibiting myostatin in animals has been 
shown to significantly increase muscle mass as well as help to preserve muscle mass in 
cases of muscle wasting diseases such as cancer cachexia (Smith & Lin, 2013). The 
myostatin signaling pathways shows how myostatin inhibitors work by causing muscles 
to hypertrophy by increasing the amounts of myofibrillar proteins (Smith & Lin, 2013). 
Myostatin works by attaching to the Activin A receptor type IIB (ActRIIb) which then 
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activates the transcription factors SMAD2 and SMAD3, and atrogene expression then 
becomes upregulated and autophagy of skeletal muscle is increased (Miyamoto, Hanna, 
Zhang, Baba, & Lenz, 2016). The mechanisms that are mainly used for myostatin 
inhibition look mostly at the receptors of myostatin and stop the receptors from binding 
myostatin (both the SMAD receptors and the ActRIIB receptors are the most understood) 
(Miyamoto et al., 2016). In a study using healthy controls and patients with untreatable 
cancer, it was found that myostatin inhibition was well tolerated by all subjects, and all 
subjects showed an increase in total muscle volume (Smith & Lin, 2013).  
In a study done using rats in a cardiac failure model of cancer cachexia, it was 
found that when myostatin levels were increased in the gastrocnemius by 140% when 
compared to the controls. In animals that were considered to be cachectic but not having 
heart failure, a significant difference was not found in the expression of myostatin (Lenk 
et al., 2009). In a study using the Yoshida AH-130 hepatoma which is known to increase 
cancer myostatin expression, levels of myostatin were found to be increased. The 
difference, however, was not shown to induce a significant difference in circulating 
myostatin levels until day 7. This led the researchers to believe that using the Yoshida 
AH-130 hepatoma is not a reliable way to look at muscle wasting in cachexia (Costelli et 
al., 2008). It has been speculated that TNF-α may be a player in perturbations in 
myostatin (Costelli et al., 2008) as it was shown that there has been a decrease in the 
ActIIB receptor activity. It has also been shown that with myostatin deficiency, not only 
is protein synthesis increased but protein degradation also becomes increased which 
could also contribute to the muscle mass increasing in size (Mendias, Kayupov, Bradley, 
Brooks, & Claflin, 2011; Smith & Lin, 2013). In a study using tumor-bearing mice, it was 
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found that knockout mice lacking myostatin had a decreased tumor weight compared to 
the wild type mice with myostatin. This points to the fact that myostatin inhibition could 
also be helpful in decreasing tumor size (Miyamoto et al., 2016).  
Myostatin and Exercise 
In general, it is well known that myostatin levels decrease with both endurance 
and resistance training. This concept has been applied in a few studies that included 
looking at myostatin and exercise, but there are fewer studies that have explored what 
happens to myostatin levels with exercise and cachexia or other muscle wasting diseases. 
In a study that used mice and both aerobic and resistance training, it was found that 
myostatin levels were decreased significantly (37%) with either type of exercise (Hittel et 
al., 2010). This study also looked at insulin resistance with the decrease in myostatin. It 
was found that there was an 87% decrease in insulin-stimulated phosphorylation of AKT 
in the mice that were treated with myostatin. This suggests that there could be an 
important link between inactivity and insulin resistance with conditions such as obesity 
(Hittel et al., 2010).  
Muscle Ring Finger 1 
Muscle Ring finger 1 (MuRF-1) is known as a negative regulator of skeletal 
muscle growth. MuRF-1 and muscle atrophy F box/atrogin 1 are associated with diseases 
that include muscle atrophy (Bodine & Baehr, 2014). The more MuRf-1 gene present, the 
higher the occurrence of atrophy. When transcription of skeletal muscle-specific E3 
ubiquitin ligases become upregulated, they cause MuRF-1, Maxfb, and atrogin-1 to be 
transcribed (Lenk et al., 2010). MuRF-1 and atrogin-1 are two of the main ligases that 
identify proteins that need to be degraded in skeletal muscle in order to decrease skeletal 
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muscle atrophy (Bowen et al., 2015). Upregulation of MuRF-1 is known to occur in 
cancer cachexia (Pigna et al., 2016). Deubiquitinases have also been found to be elevated 
with cachexia to help regenerate the free ubiquitin from the ubiquitin chain (Bowen et al., 
2015). MuRF-1 as well as MAFbx have been found to be upregulated when the ubiquitin 
proteasome pathway becomes upregulated (Bowen et al., 2015). In a model where the 
hind limbs of the rat were unloaded, MuRF-1 was found to be upregulated with muscle 
atrophy (Bodine & Baehr, 2014). MuRF-1 is known to interact with key proteins of the 
sarcomere such as titin, myosin light chain, myosin heavy chain, and nebulin. While this 
is known, it is not well identified how MuRF-1 interacts with these proteins. In a study 
done using dexamethasone treatment it was found that myosin heavy chain can be 
preserved if MuRF-1 is downregulated, meaning if MuRF-1 can become downregulated 
there may be a protective effect for the sarcomeres in skeletal muscle (Clarke et al., 
2007). MuRF-1 is downstream of atrogin 1 and FoxO proteins which become upregulated 
with the autophagy pathways. When autophagy becomes upregulated, MuRF-1 becomes 
upregulated leading to increased degradation of skeletal muscle (Miyamoto et al., 2016). 
MuRF-1 regulates E3 ubiquitin ligase activity, and therefore if MuRF-1 becomes 
upregulated, E3 ubiquitin ligase activity becomes upregulated and causes skeletal muscle 
to be degraded through that pathway (Miyamoto et al., 2016).  
Muscle Ring Finger 1 and Exercise 
Because MuRF-1 is known as a negative regulator of skeletal muscle, it is known 
to decrease with increased exercise. In a study done using patients with chronic heart 
failure it was found that those with prescribed exercise were able to decrease levels of 
MuRF-1. This led to the overall conclusion that an increase in exercise can aid in 
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blocking the ubiquitin proteasome pathway which would then decrease the amount of 
muscle atrophy taking place overall (Gielen et al., 2012). In a study using voluntary 
wheel running in a C26 tumor model, it was shown that as exercise downregulates 
MuRF-1. With a decrease in MuRF-1 expression there was also a decrease in skeletal 
muscle degradation (Pigna et al., 2016).  
Conclusion 
Cancer cachexia is known to severely decrease skeletal muscle mass to the point 
where it is difficult for cancer patients to perform normal activities of daily living. 
Overall, it is well known that exercise helps increase muscle mass regardless of the mode. 
Exercise protocols included with cancer cachexia have been found to be an effective way 
of combatting some of the negative side effects of cancer cachexia. With exercise, 
myogenic regulatory factors such as MyoD and myogenin are known to become 
upregulated, while myostatin and MuRF-1 become downregulated. By including exercise 
in treatment for cancer cachexia, it is possible that the positive myogenic regulatory 
factors, MyoD and myogenin may become upregulated while the negative regulators such 
as myostatin and MuRF-1 become downregulated. If myogenin and MyoD become 
upregulated, there is an increase in the anabolic pathways leading to muscle hypertrophy.  
When myostatin and MuRF-1 are downregulated, they decrease the amount of skeletal 
muscle wasting. By understanding what happens to the positive myogenic regulatory 
factors such as MyoD and myogenin as well as the negative myogenic regulatory factors 
such as myostatin and MuRF-1 in cancer cachexia and how they can become up- or 
downregulated with exercise, treatments can be more targeted and increase a patient’s 
quality of life.   
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CHAPTER III 
 
MATERIALS AND METHODS 
 
Experimental Design 
The effects of exercise were looked at using various exercise approaches that 
spanned over eight weeks. Male Balb/c mice (n=60) were randomly assigned to one of 
five groups: sedentary control group (Sed+Control), sedentary and tumor group 
(Sed+Tumor), treadmill training and tumor group (TM+Tumor), resistance training and 
tumor group (RT+Tumor), and combined treadmill training and resistance training and 
tumor group (COMBO+Tumor). Mice were randomly assigned to groups at six weeks of 
age. The mice assigned to the tumor bearing groups were injected with 1x106 C26 tumor 
cells. The sedentary control group did not receive C26 cells to act as the non-tumor 
control. Upon sacrifice the gastrocnemius was harvested, weighed, and prepared for 
biochemical analysis.  
Animals and Animal Care 
All procedures used in this study complied with the Animal Welfare Act guidelines and 
were approved by the University of Northern Colorado Institutional Animal Care and Use 
Committee (IACUC). Male Balb/c mice (The Jackson Laboratory; Bar Harbor, ME; 
stock #000651; n = 60) were housed at the University of Northern Colorado Animal 
Research facility. They were given chow and water at libitum and housed one per cage in 
a 12:12-hour light-dark cycle in a temperature-controlled facility.  
 
   
 
19  
 
 
Exercise Training Protocol 
For the endurance training protocol, animals that were randomly selected to the 
TM+tumor group were housed in cages with a standard height of 12.5 cm for the full 
eight week intervention. All animals assigned to the TM+tumor group were acclimatized 
to the treadmill for 3 days before the protocol started. Acclimation to the treadmill was 
done by gradually increasing the speed of the treadmill by 10-15 m/min for 20 min. The 
full running protocol for the intervention included a 5 minute warm up at a grade of 5% 
with a speed of 15 m/min. This was then followed by a period of running at 15 m/min 
with a 5% grade. The mice ran 5 days per week for the duration of eight weeks. This was 
done during their dark cycle under red lights.  
For the resistance training protocol, the mice that were randomly selected to the 
RT+tumor group were housed in a standard cage (12.5 cm). Cage height was 
progressively increased from the starting height of 12.5 cm. This forced the mice to stand 
on their hind limbs in order to reach the food and water. When the exercise training 
protocol began, mice were moved to cages with a height of 15.5 cm for the first week. 
The next week, the cage height was increased to 18 cm which was maintained for the rest 
of the eight week intervention. For the first three weeks of the intervention, body mass, 
food, and water were monitored every day to ensure the mice were able to reach their 
food and water. After the third week, food and water were measured three days per week 
while body mass was measured one day per week throughout the exercise protocol. 
Animals assigned to the COMBO+tumor group followed both the endurance and 
resistance training protocols. The mice were only removed from their cages for treadmill 
training sessions. Figure 1 shows a visual representation of the experimental design. 
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Groups   n 
Sed+Control  12 
Sed+Tumor  12 
RT+Tumor  12 
TM+Tumor  12 
COMBO+Tumor 12 
Timeline 
 
Figure 1. Experimental design 
Note. Sed, sedentary; TM, treadmill trained, RT, resistance trained, COMBO, treadmill 
and resistance trained 
 
 
C26 Cell Culture Inoculation 
The colon-26 (C26, DCTD Tumor Repository, National Cancer Institute; 
Frederick, MD) cells were suspended in Roswell Park Memorial Institute (RPMI) 1640 
complete growth medium containing 10% FB Essence, 1% L-glutamine, and 1% 
streptomycin/penicillin and grown at 37°C in an incubator with an atmosphere that 
contained 5% CO2. The cells were counted using a commercial cell counter (Invitrogen; 
Carlsbad, CA).On the day that the cells were implanted, they were dissociated using a 
trypsin-EDTA solution, and cell concentration was determined as cells/m2. The cells 
were then resuspended in sterile PBS to be used for tumor cell inoculation. Mice were 
anesthetized prior to the injection using isoflurane which was administered through 
inhalation. This was maintained throughout the time needed to perform the tumor cell 
inoculation. The cells were injected between the scapulae subcutaneously and was done 
by using a 25-guage needle with a sterile 1-mL syringe.  
6 weeks
Exercise intervention 
starts 
11 weeks 
C26 Tumor 
inoculation
14 weeks 
Sacrifice/Tissue 
harvest
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After tumor cell inoculation animals and tumors were monitored daily up until 
sacrifice. This included the relative tumor size, loss in body mass, tumor ulceration, and 
body score condition. Body weight was measured daily, and once the tumors were 
palpable, tumor size was measured daily.  Upon sacrifice, the tumors were also removed 
and weighed.  
Biochemical Analysis 
Tissue Preparation 
Gastrocnemius muscles were put into Eppendorf microcentrifuge tubes and frozen 
in liquid nitrogen upon sacrifice. Muscles were then transported back to the biochemistry 
lab and stored at -80°C until analysis.  
Homogenate Preparation 
A 0.100 g portion of each gastrocnemius sample once weighed was placed in a 
glass tissue homogenizer, and homogenized in a homogenizing buffer (250 mM Sucrose, 
100 mM KClm, 5 mM EDTA, 20 mM Tris [pH 6.8]). Homogenates were then 
centrifuged at 3,000 g and 4°C for 10 minutes. The supernatant was then removed and 
placed in a separate microcentrifuge tube. Samples were then sonicated and centrifuged 
at 10,000 g and 4°C for another 10 minutes. The supernatant was removed and placed in 
a new microcentrifuge tube. 100 µL of supernatant was combined with 100 µL of 2X 
Laemmli sample buffer.  
Western Blotting  
Western blotting was used to quantify the expression of MyoD, myogenin, 
myostatin and MuRF-1 in the gastrocnemius. All antibodies were from Santa Cruz 
Biotechnology, Inc. After samples were thawed, they were boiled for two minutes and 
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then put on ice for approximately 10 minutes. Next, 20 µL of each sample was vortexed 
and loaded onto 4-20% Invitrogen Tris-Glycine precast polyacrylamide gels (Thermo 
Fischer Scientific, Waltham, MA). Once the gels were loaded, they were run at 125 V at 
40 mA until the proteins migrated to the bottom of the gel which took approximately two 
and a half hours.  
Proteins were then transferred from the gel to PVDF membranes. This process 
was done over 90 minutes at 25 mV and 100 mA. The transfer was ensured by presence 
of the SeeBlue Plus2 protein ladder on the membrane (Novex, LifeTechnologies). PVDF 
membranes were then rinsed in deionized water 3 timed for 5 minutes and then blocked 
for 30 minutes using 10 mL of Superblock (Thermo Fischer Scientific, Waltham, MA). 
They were then rinsed again deionized water 3 times for 5 minutes and incubated over 
night for 15-18 hours with the primary antibody. The next day membranes were washed 
in TBST for 5 minutes 4 times then rinsed with deionized water for 5 minutes 3 times and 
incubated in the appropriate secondary antibody for 60 minutes. The membranes were 
again washed in TBST 4 times for 5 minutes and rinsed in deionized water 3 times for 5 
minutes. The membranes were then prepared for imaging.  
Membranes were incubated in enhanced chemiluminescence (ECL) substrate to 
initiate the imaging process. Imaging was done using a C-Digit imaging system (Li-Cor: 
Licoln, NE), and protein bands were quantified using ImageJ software (NIH: Bethesda, 
MD). After the membranes were imaged, they were stripped using 10 mL stripping buffer 
(Invitrogen) 2 times for 20 minutes, washed in 20 mL of TBST 4 times for 5 minutes, and 
rinsed in 20 mL of deionized water three times for two minutes. The process of 
membrane blocking and primary antibody incubation was then repeated. Each membrane 
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was imaged with each of the four primary antibodies as well as GAPDH which was used 
to normalize the amount of protein in each sample.  
Statistical Analyses 
Data are presented as mean±SEM, and all statistical analyses were performed 
using GraphPad Prism. A one-way analysis of variation (ANOVA) was used to identify 
the differences in myogenic regulatory factors between groups. When a significant F-
value was observed, Tukeys post hoc test was performed to determine where the 
significant differences existed. Significance was set at the α=0.05 level. 
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CHAPTER IV 
RESULTS  
The purpose of this study was to determine the effects of an endurance training 
protocol, a resistance training protocol, and a combined endurance and resistance training 
protocol in cancer cachexia on the myogenic regulatory factors MyoD, myogenin, 
myostatin, and MuRF-1. This study examined both positive and negative  myogenic 
regulatory factors to determine which pathways are more or less affected by cancer 
cachexia in exercise.   
 As shown in Figure 2, there were no significant group differences for increases in 
the expression of MyoD (p>0.05) 
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Figure 2. MyoD expression levels in the Gastrocnemius and representative immunoblots 
of MyoD and GAPDH. OD=optical density, Sed+control, n=12, Sed+Tumor, n=12, 
TM+Tumor, n=12, RT+Tumor, n=12, COMBO+Tumor, n=12. Values are means ± SEM. 
 
 
As shown in Figure 3, there were no significant group differences in the 
expression levels of myogenin (p>0.05).  
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Figure 3. Myogenin expression levels in the Gastrocnemius and representative 
immunoblots of myogenin and GAPDH. OD=optical density, Sed+control, n=12, 
Sed+Tumor, n=12, TM+Tumor, n=12, RT+Tumor, n=12, COMBO+Tumor, n=12. 
Values are means ± SEM. 
 
 
 
As shown in Figure 4, there was a significant group difference in myostatin 
expression (p<0.05). Post hoc testing revealed that there was significantly lower 
myostatin expression in the Sed+Tumor group when compared to the each of the exercise 
tumor groups. More specifically, the significant differences were found between 
Sed+Tumor and TM+Tumor, Sed+Tumor and RT+Tumor , and Sed+Tumor and 
COMBO+Tumor (p<0.05). The largest difference was observed between the Sed+Tumor 
and COMBO+Tumor group (p<0.01). 
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Figure 4. Myostatin expression levels in the Gastrocnemius and representative 
immunoblots of myostatin and GAPDH. OD=optical density, Sed+control, n=12, 
Sed+Tumor, n=12, TM+Tumor, n=12, RT+Tumor, n=12, COMBO+Tumor, n=12. 
Values are means ± SEM. p<0.05  
*significantly different from Sed+Tumor 
 
As shown in Figure 4, there were no significant group differences in the 
expression of  MuRF-1 (p>0.05) However, there was be a trend showing and increased 
expression of myostatin and MuRF-1 in the Sed+Tumor group as compared to the 
exercise groups. There was also a trend showing a decreased amount of MuRF-1 in the 
exercised groups as compared to the SED+Tumor group. For both of the negative 
myogenic regulatory factors, myostatin and MuRF-1 the COMBO+Tumor group look to 
have the largest decrease in protein expression.  
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Figure 4. MuRF-1 expression levels in the Gastrocnemius and representative 
immunoblots of MuRF-1 and GAPDH. OD=optical density, Sed+control, n=11, 
Sed+Tumor, n=12, TM+Tumor, n=12, RT+Tumor, n=12, COMBO+Tumor, n=11. 
Values are means ± SEM  
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CHAPTER V 
 
DISCUSSION 
 
This study examined the effects of an endurance training protocol, a resistance 
training protocol, and a combined endurance and resistance training protocol in cancer 
cachexia on the positive myogenic regulatory factors MyoD and myogenin, as well as the 
negative myogenic regulatory factors myostatin and MuRF-1. The main finding of this 
study revealed that SED+Tumor had significantly higher myostatin than TM+Tumor, 
RT+Tumor, and COMBO+Tumor. This means that any type of exercise led to significant 
decreases in myostatin expression with cancer cachexia. It has been well established that 
exercise leads to metabolic changes that typically increase the positive regulators of 
muscle growth such a MyoD and myogenin and decrease the negative regulators of 
muscle growth such as myostatin and MuRF-1.  
This study did not find significant differences in the levels of MyoD. This could 
be due to a number of factors, one being that there was either too little or too much 
stimulus. In Figure 2, it is shown that while there are no significant group differences, the 
group that had a trend toward the highest amount of MyoD expression was the resistance 
training group. This finding is consistent with data found in other experiments where 
MyoD was shown to increase with mechanical stimulation as well as with stimulation 
that is known to induce satellite cell proliferation (Legerlotz & Smith, 2008). It would be 
expected that MyoD would increase in response to resistance exercise, as that is one way 
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in which satellite cells in skeletal muscle are proliferated (Megeney et al., 1996). In a 
different arm of this study that was performed it was found that the only significant 
differences in cross sectional area of the gastrocnemius were between the Sed+control 
group and the Sed+tumor group (Wood, 2019). This means that the while there was not a 
significant decrease in muscle mass, there was also not a significant increase in muscle 
mass. Overall there may not have been enough stimulus to induce muscle hypertrophy 
during cachexia.  
This study also found that there were no group differences in expression of 
myogenin. In Figure 3, a trend toward the levels of myogenin being decreased was 
observed in the exercise groups compared to both the Sed+Control and the Sed+Tumor 
group. While there were no significant group differences, myogenin may not have been 
upregulated due to the fact that there could have been more mitochondrial damage than 
expected due to cancer cachexia. In other studies, it has been found that damaged 
mitochondria could cause myogenin not to be expressed (Megeney et al., 1996). This 
would also go along with the fact that myogenin is involved in the satellite cell cycle. 
Therefore, if the muscles are not hypertrophying, then the myogenic regulatory factors 
that are involved in that process will not likely be upregulated (Ishido et al., 2004). It has 
also been shown that when muscles stop hypertrophying and are in a stage of 
maintenance, myogenin tends to not be expressed (Ishido et al., 2004). As stated before, 
there may not have been enough stimulus to lead to skeletal muscle hypertrophy, or the 
cachexia could have led to a significantly lower baseline of the positive myogenic 
regulatory factors; meaning it would be more difficult for there to be an overall increase 
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compared to the Sed+Control group in MyoD and myogenin expression. In future 
studies, mitochondrial damage should be taken into consideration.  
 This study found significant decreases in the levels of myostatin that were 
expressed in the exercised tumor groups when compared to the sedentary tumor group. 
Tukey’s post hoc testing revealed that the significant group differences were between the 
Sed+Tumor group and each of the exercise groups. The largest decrease was shown in 
the COMBO+Tumor group suggesting that the combination training approach had a trend 
toward the largest effect on myostatin expression. This finding is the similar to findings 
in other research, in that the downregulation of myostatin does tend to have a protective 
effect on skeletal muscles with cancer cachexia (Smith & Lin, 2013). While myostatin is 
known to be upregulated in cachectic models, it is known to decrease with exercise. This 
study confirms that with any mode of exercise, myostatin will be downregulated. While 
the downregulation of myostatin was most prevalent in the combined endurance and 
resistance training group, there was also a significant difference between the Sed+Tumor 
and TM+Tumor groups as well as a significant difference between Sed+Tumor and 
RT+Tumor groups. This shows that there is a chance to downregulate myostatin with any 
mode of exercise. This is consistent with others who used both endurance and resistance 
training to promote a significant decrease in myostatin expression (Hittel et al., 2010).  
 The final myogenic regulatory factor that was examined was MuRF-1. While 
there were no significant group differences found, there does seem to be a trend toward 
MuRF-1 being decreased with exercise as shown Figure 5. It is well known that when 
MuRF-1 is upregulated, muscle atrophy is stimulated (Bowen et al., 2015). While the 
decrease of MuRF-1 was not significant, it was also found that there were no significant 
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decreases in skeletal muscle mass of the gastrocnemius (Wood, 2019). This is consistent 
with another study that used wheel running as a way to decrease MuRF-1 levels (Pigna et 
al., 2016). MuRF-1 is downregulated with exercise under normal control conditions; 
however it also tends to be upregulated with cancer cachexia (Bodine & Baehr, 2014). 
This study did look at both cancer cachexia and exercise. While there were not significant 
MuRF-1 decreases with exercise, it was shown that there was an overall protective effect 
on the gastrocnemius with the exercise protocols. This was shown though through the 
fact that there was not a significant decrease in the cross-sectional area of the 
gastrocnemius, which was observed in a separate arm of this study (Wood, 2019).  
 While there were no significant differences in the positive myogenic regulatory 
factors with exercise, there was a significant decrease in one of the negative myogenic 
regulatory factors with exercise and a trend toward a decrease the other negative 
myogenic regulatory factor. While trying to stimulate hypertrophy in skeletal muscles 
during cancer cachexia is important, it may be just as important to protect the skeletal 
muscles from atrophy. With cancer cachexia it is prevalent that muscle metabolism is 
changed and the positive myogenic regulatory factors decrease in expression and the 
negative myogenic regulatory factors increase in expression. It is now a matter of 
understanding how exactly these pathways become affected in cancer cachexia with 
exercise, as it has been shown that exercise can prove beneficial in decreasing the amount 
of skeletal muscle wasting. It may be difficult for there to be a significant increase in the 
positive myogenic regulatory factors such as MyoD and myogenin as both are involved 
in the satellite cell activation and the hypertrophy of skeletal muscle. If there is not 
enough stimulus for satellite cells to proliferate, then changes in MyoD and myogenin 
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will not be prevalent enough to be detected. The currently accepted mechanism behind 
cancer cachexia is shown through a decrease in cross sectional area of the myofibers and 
not necessarily a decrease in muscle myofiber number (Ishido et al., 2004). As far as the 
negative myogenic regulatory factors go, there was a significant decrease in the amount 
of myostatin expression and a trend toward a decrease in the level of MuRF-1. With these 
factors showing a decrease expression with exercise, it is shown that the negative 
regulators of skeletal muscle are easier to manipulate then the positive regulators of 
skeletal muscle growth. It also shows that while the exercise was not enough for the 
skeletal muscles to hypertrophy, the decreases in the negative myogenic regulatory 
factors did has a protective effect. The combination group may have showed the largest 
decrease because they did have the greatest overall volume of work suggesting that those 
muscles got the largest amount of stimulus. This could have been a main factor in why 
the combination group showed the largest decrease in both myostatin and MuRF-1 
expression.  
Conclusion and Further Applications 
 While cancer cachexia is known to affect a large portion of the cancer population, 
it is important to find the underlying mechanisms of skeletal muscle wasting. Exercise, 
while it is not a treatment, has been shown to negate some of the effects of cancer 
cachexia such as muscle wasting (Porporato, 2016). Overall, the current study showed 
that the negative regulators of skeletal muscle growth may be just as important to take 
into consideration as the positive regulators of skeletal muscle growth. Further research 
should look more into specific modes of exercise with cancer cachexia. A combination of 
endurance and resistance training led largest affect in this study, it could be important to 
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increase volume of the endurance and resistance training protocols. This will help ensure 
that the type of exercise performed led to the specific changes in the myogenic regulatory 
factors, and that it was not just the increased volume in the combination group that led to 
these changes.  
 This study could also have clinical applications leading to the inclusion of 
exercise protocols in cancer patients with cachexia could help increase quality of life. 
Exercise interventions could lead to less skeletal muscle wasting allowing patients to 
have an easier time performing activities of daily living. The less skeletal muscle mass 
that a patient loses, typically the better the prognosis (Lenk et al., 2010). This suggests 
that if there is an exercise approach that can help decrease the expression of negative 
myogenic regulatory factors, it should be taken into consideration as part of the patient’s 
treatment.  
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